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Abstract
Background: To assess the demographic and attitudinal factors associated with HPV vaccine initiation and completion
among 18–26 year old women in Utah.
Method: Between January 2013 and December 2013, we surveyed 325 women from the University of Utah Community
Clinics about their HPV vaccine related beliefs and behaviors. Odds ratios (ORs) were estimated from logistic regression
models to identify variables related to HPV vaccine initiation and series completion.
Results: Of the 325 participants, 204 (62.8 %) had initiated the vaccine and 159 (48.9 %) had completed the 3-dose series.
The variables associated with HPV vaccine initiation were lower age (OR = 1.18 per year); being unmarried (OR = 3.62); not
practicing organized religion (OR = 2.40); knowing how HPV spreads (OR = 6.29); knowing the connection between HPV
and cervical cancer (OR = 3.90); a belief in the importance of preventive vaccination (OR = 2.45 per scale unit); strength of
doctor recommendation (OR = 1.86 per scale unit); and whether a doctor’s recommendation was influential (OR = 1.70
per scale unit). These variables were also significantly associated with HPV vaccine completion.
Conclusion: The implications of these findings may help inform policies and interventions focused on increasing HPV
vaccination rates among young women. For example, without this information, programs might focus on HPV
awareness; however, the results of this study illustrate that awareness is already high (near saturation) in
target populations and other factors, such as strong and consistent physician recommendations, are more
pivotal in increasing likelihood of vaccination. Additionally, our findings indicate the need for discussions of
risk assessment be tailored to the young adult population.
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Background
The American Cancer Society estimates that in 2014, there
will be over 12,000 new cases of invasive cervical cancer
diagnosed in the United States and over 4,000 women will
die from this disease [1]. Human papillomavirus (HPV), the
most common sexually transmitted infection [2, 3], has
been shown to be necessary to cause cervical cancer [4–6].
Recognition of this link led to the development of vaccines
protecting against infection with certain high-risk types of
HPV. There are currently two HPV vaccines available:
Merck’s Gardasil® vaccine [7], proved highly effective in
preventing the highest prevalence HPV types 16 and 18
(which cause up to 70 % of all cervical cancers), as well as
HPV types 6 and 11 (which cause about 90 % of genital
warts) [4, 8–10]; and GlaxoSmithKline’s Cervarix® vaccine
[11], targeting the two most common oncogenic HPV types
(16 and 18) [4, 10].
In 2006, the Centers for Disease Control (CDC) Advisory
Committee on Immunization Practices (ACIP) recom-
mended a 3-dose HPV vaccination series as a routine
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vaccine for girls age 11–12 years old [12]. Vaccine ad-
ministration is optimal at this age because adolescents
have the best immunoresponse to the vaccine and likely
have not yet been exposed to the virus [12]. However,
the ACIP also recommended the HPV vaccination series
as a catch-up vaccine for young women age 13–26 years
old [12]. Additionally, these recommendations have been
extended to include males. It is hypothesized that with
good vaccination coverage, the prevalence of HPV and
HPV-associated cancers will decline [5, 12–14].
Despite this opportunity for cervical cancer prevention,
HPV vaccination rates are low in the United States. In
2013, just 57.3 % of adolescent girls age 13–17 years old
had received one dose of the vaccine, and only 37.6 % had
completed the three-dose series [15]. Coverage is espe-
cially poor in Utah, with just 44.3 % of Utah adolescent
girls initiating the vaccine, and 20.5 % completing the 3-
dose series [15]. Most recent data indicates that uptake is
the worst among young women: only 34.5 % of women
age 19–26 years old report receiving at least one dose of
the HPV vaccine [16]. State-specific data for this age
group is unavailable. In spite of this low HPV vaccine
coverage, recommendations from physicians remain sub-
optimal for all age groups [17].
While the choice whether or not to vaccinate adoles-
cent usually falls to their parents, young women who are
eligible to receive the vaccine are able to make the deci-
sion for themselves. These women are responsible for
their own health, so their attitudes towards receiving the
HPV vaccine and their decision-making processes may
be different from those of the parents of young adoles-
cents. There have been many studies on women’s beliefs
and behaviors related to the HPV vaccine, but few stud-
ies have specifically focused on a state with low HPV
vaccine initiation and completion rates [18–25].
The purpose of this study is to assess the demographic
and attitudinal factors associated with HPV initiation
and completion among 18–26 year old women in Utah.
Our goal is to generate information to develop interven-
tion programs to increase HPV vaccination in this age
group in Utah.
Methods
This study was approved by the University of Utah
Institutional Review Board.
Survey development
Previous studies have used Health Belief Model (HBM)
constructs [26, 27] and/or Social Cognitive Model (SCM)
factors [28, 29] to identify predictors of HPV vaccination
intention. The HBM considers potential motivating factors
such as perceived severity (an individual’s assessment of
the seriousness of the condition), perceived susceptibility
(an individual’s assessment of their risk of getting the
condition), expected benefit (an individual’s assessment of
the positive rewards of adopting the behavior), self-efficacy,
and perceived barriers [30]. Whereas SCM also incorpo-
rates a person’s social environment, e.g., peer group, and
observational learning on their health behaviors [29]. Each
question included in our survey corresponded to a concep-
tual variable representing one facet in either HBM or SCM
[29, 30]. Survey items were also motivated by use of di-
rected acyclic graphs and a survey developed by other re-
searchers and shared with permission [23, 31].
Our study questionnaire included six sections:
(1)Attitudes about health,
(2)Attitudes about vaccines,
(3)Demographic information and history/family history
of cancer,
(4)Attitudes about reproductive health,
(5)Attitudes about the HPV vaccine, and
(6)Future (intended) HPV vaccine use.
Data collection
A Survey sampling flow diagram representing recruitment
is presented in Fig. 1. We recruited participants from the
University of Utah Community Clinics through the
University of Utah Primary Care Research Network. An
initial data query of potential participants was performed to
identify young women age 18–26 years old who had a
University of Utah Community Clinic visit in the 12 months
preceding the query. Two groups of 1,000 were created. In
the first group, we included 336 women who had at least
one documented dose of the HPV vaccine and 664 unvac-
cinated women. In the second group we included 233 who
had initiated the vaccine and 776 unvaccinated women.
Potential participants were sorted by zip code and only
those within the catchment areas for the University of Utah
Community Clinics were included in the sample. Potential
participants were mailed a letter briefly describing the pro-
ject and given the opportunity to opt out. Remaining partic-
ipants were mailed a letter describing the project in greater
detail, a paper version of the survey, and a business reply
envelope to return the survey.
Introduction letters with study opt-out information
went out in two waves of 1,000. The initial wave of 1,000
opt-out letters was sent out in January 2013. After exclud-
ing nine opt-outs, we had a response rate of 84 of 991 sur-
veys (8.5 %). The target response rate for analysis was
between 300–325 completed surveys. In order to improve
return rates, the implementation protocol was revised, fol-
lowing the Tailored Design Method proposed by Dillman,
et. al. [32]. Modifications to the survey wave, according to
the Dillman method, included:
 1,000 Opt-out letters and cover letters were printed
in high-resolution color and hand-signed,
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Fig. 2 DAG showing potential cofounders of predictors of HPV vaccine uptake (Utah, January December 2013)
Fig. 1 Survey sampling flow diagram (Utah, January-December 2013)
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 Surveys now included a 5$ bill thank you with
return envelope, and
 Address verification services were used.
These revisions bolstered returns from 8.5 % to over
27.1 % (244 surveys completed of 901 delivered). All sur-
veys were mailed between January and December 2013.
Data analysis
Fisher’s Exact Tests and Logistic Regression were used
to determine differences in demographics, initiation, and
completion rates between the two waves of survey re-
sponses to assess appropriateness of pooling results.
Summary statistics for participant characteristics were
calculated by vaccination status. Principal component
factor analysis with promax rotation was used for the
attitude questions to derive useful attitude factor vari-
ables. Correlation between items in factor variables
was assessed using Cronbach’s alpha (Table 3).
A Directed Acyclic Graph (DAG) (Fig. 2) was created to
help identify and adjust for potential confounders and
minimize bias assessing individual predictors of vaccine
Table 1 Characteristic of study participants (Utah, January-December 2013)
No doses (n = 121)
n (%)
1+ dose (n = 204)
n (%)
3 dose completion (n = 159)
n (%)
Age
18–21.5 y.o. 28 (23.14) 82 (40.20) 65 (40.88)
22–24 y.o. 48 (39.67) 70 (34.31) 53 (33.33)
24.5–26 y.o. 45 (37.19) 52 (25.49) 41 (25.79)
Race/ethnicity
Asian 9 (7.44) 8 (3.92) 8 (5.03)
Black or African American 2 (1.65) 4 (1.96) 3 (1.89)
Hispanic or Latina 9 (7.44) 15 (7.35) 10 (6.29)
White/Caucasian 96 (79.34) 167 (81.86) 133 (83.65)
Other 5 (4.13) 10 (4.90) 5 (3.14)
Highest level of education
Up to or graduated high school 24 (19.83) 25 (12.25) 17 (10.69)
Some college, but no degree 39 (32.23) 90 (44.12) 72 (45.28)
College degree 46 (38.02) 77 (37.75) 60 (37.74)
Graduate school 12 (9.92) 12 (5.88) 10 (6.29)
Marital status
Single, never married 66 (54.55) 165 (80.88) 132 (83.02)
(Ever) Married 54 (44.63) 38 (18.63) 26 (16.35)
Ever received a cancer diagnosis
Yes 3 (2.48) 3 (1.47) 2 (1.26)
No 118 (97.52) 199 (97.55) 155 (97.48)
Know anyone who has had a cancer diagnosis
Yes 95 (79.51) 178 (87.25) 140 (88.05)
No 26 (21.49) 26 (12.75) 19 (11.95)
Know anyone who has had cervical cancer
Yes 9 (9.57) 24 (13.04) 18 (12.59)
No 85 (90.43) 160 (86.96) 125 (87.41)
Practice organized religion
Yes 72 (59.50) 75 (36.95) 53 (33.54)
No 49 (40.50) 128 (63.05) 105 (66.46)
Religion guide your daily decisions
Yes 57 (65.52) 51 (48.57) 38 (48.10)
No 30 (34.48) 54 (51.43) 41 (51.90)
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initiation (1+ dose) and series completion (3 doses) [33,
34]. An online tool, DAGitty (http://www.dagitty.net), was
used to produce potential DAGs and derive minimally suffi-
cient adjustment sets for predictor variables [35]. Univariate
and multivariable logistic regression models were used to
calculate odds ratios (ORs) to identify variables related to
vaccine initiation and series completion.
Factor and Principal Component Analysis was performed
using R (R Core Team, 2013). Descriptive statistics and uni-
variate and multivariable logistic regression was performed
using SAS software, Version 9.4. Results were considered
statistically significant if p < 0.05.
Results
A total of 84 of 993 surveys (8.5 %) from the first wave
and 244 of 901 surveys (27.1 %) from the second wave
were returned for a total of 328 of 1,983 returned
(16.5 %). Three participants were excluded: two for hav-
ing an age out of range and one for incompleteness of
the questionnaire. The remaining 325 were included in
the final analysis. There were no statistically significant
differences between the two survey waves, and the only
difference between wave one and wave two was wave
two included a small incentive, but otherwise was drawn
from the same population. Therefore, the two waves
were pooled for the analysis.
Of these 325 participants, 204 (62.8 %) had initiated
the vaccine series and 159 (48.9 %) had completed the 3-
dose series. Of the 45 who had initiated, but not com-
pleted the vaccine series, 31 (70.5 %) said they intended
to complete the series and 13 (29.6 %) said they did not
(one missing). The mean age for those who initiated the
vaccine was 22.4 years (s.d. 2.4 years), for those who com-
pleted the 3-dose series was 22.4 years (s.d. 2.4 years), and
for those who did not receive any vaccine doses was
23.3 years (s.d. 2.3 years). Participant characteristics are
presented in Table 1 and participants’ HPV vaccine related
knowledge and attitudes are presented in Table 2.
The factor analysis produced a total of seven attitude
factors with good inter-item correlation, presented in
Table 3. Table 4 shows the significant univariate predictors
of vaccine initiation were lower age vs. older age: OR = 1.18
per lower year [95 % CI: 1.07–1.30]; marital status (being
unmarried vs. married): OR = 3.62 [95 % CI: 2.18–5.99]; not










Have you ever heard of human papillomavirus (HPV)?
Yes 105 (86.78) 200 (98.04) 155 (97.48)
No 16 (13.22) 4 (1.96) 4 (2.52)
Do you know how HPV is spread?
Yes 72 (59.50) 185 (90.69) 144 (90.57)
No 49 (40.50) 19 (9.31) 15 (9.43)
Have you ever heard of a relationship between HPV and cervical cancer?
Yes 78 (65.00) 180 (88.24) 143 (89.94)
No 42 (35.00) 24 (11.76) 16 (10.06)
Have you ever heard of a vaccine to prevent HPV (e.g., Gardasil® or Cervarix®)?
Yes 90 (75.00) 203 (100) 158 (100)
No 30 (25.00) 0 (0) 0 (0)
(If heard of vaccine) how important do you think the vaccine to help prevent cervical cancer is for you?
Not at all important 10 (11.11) 5 (2.45) 2 (1.26)
Not very important 18 (20.00) 6 (2.94) 0 (0)
Somewhat important 27 (30.00) 50 (24.51) 33 (20.75)
Very important 35 (38.89) 143 (70.10) 124 (77.99)
Have you discussed the vaccine to help prevent cervical cancer with a doctor?
Yes 34 (37.36) 201 (98.53) 158 (99.37)
No 57 (62.64) 3 (1.47) 1 (0.63)
Did a doctor recommend that you get the vaccine to help prevent cervical cancer?
Yes 22 (55.00) 199 (98.03) 157 (99.37)
No 18 (45.00) 4 (1.97) 1 (0.63)
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practicing vs. practicing organized religion: OR = 2.4 [95 %
CI: 1.49–4.0]; knowledge of HPV transmission: OR = 6.29
[95 % CI: 3.46–11.44]; known connection between HPV
and cervical cancer: OR = 3.90 [95 % CI: 2.21–6.89]; known
importance of vaccine (to help prevent cervical
cancer): OR = 2.45 [95 % CI: 1.79–3.36]; strength of
doctor recommendation: OR = 1.86 per Likert scale
unit [95 % CI: 1.27–2.70]; and a binary indicator of
whether a physician’s recommendation is influential:
OR = 1.70 [95 % CI: 1.38–2.09]. These variables were
all also significant predictors of completion of the 3-
dose series (see Table 4). Minimal sufficient adjustment
sets were derived from application of the DAG (see
Fig. 2) to produce subsets of variables adequate to con-
trol for potential confounding. These subsets were
used to produce adjusted estimates (see Table 4).
The main reasons for not intending to initiate or
complete the vaccine were waiting for more informa-
tion/vaccine too new (n = 38), married or monogam-
ous relationship (n = 36), cost of vaccine or unsure if
insurance covers vaccine (n = 23), concern of side ef-
fects (n = 18), not sexually active (n = 14), and vaccine
inconvenience (n = 7) (see Fig. 3).
Discussion
The HPV vaccine has been available in the United States
for eight years, yet only one third of adolescents have
been fully immunized with all three recommended
doses, and only one third of older eligible women (age
18–26 years old) have received just one dose of the 3-
dose series [12, 15, 16]. HPV vaccine coverage varies
substantially among states, with Utah having some of
the lowest coverage rates in the U.S. [15]. Clearly, the
Unites States is far from the Healthy People 2020 target
of 80 % HPV vaccine coverage among eligible females,
indicating an urgent need for interventions [15].
Resources are currently available to help increase HPV
vaccination in Utah. In April 2007, Jon Huntsman, Sr.
donated $1 million to the Utah Department of Health to
educate Utahans about cervical cancer and provide low
cost HPV vaccines to eligible women [36]. An additional
$25,000 allocated by the Utah legislature was used for a
public awareness media campaign and to inform physi-
cians and other health care professionals about the HPV
vaccine [36]. Additionally, the HPV vaccine is available
for free or at low cost for girls age 9–18 years old
through the Vaccines for Children Program and may be
available for free or at low cost for women age 19–26
years old who have no insurance or insurance that does
not pay for the vaccine thanks to Vaccine Patient Assist-
ance Programs [37, 38]. The results of our study can
help to focus these funds and resources to reach women
who have not yet initiated and/or completed the HPV
vaccination series.
Our study of young women age 18–26 years old
found several correlates of vaccine initiation and com-
pletion that may be useful for future public health
interventions for this population. Among these corre-
lates were lower age, awareness of HPV transmission,
knowledge of its connection to cervical cancer, belief
in the importance of the HPV vaccine, and a physician
recommendation (especially a strong recommenda-
tion) (Additional file 1: Figure S1). Marital status (be-
ing unmarried), practicing organized religion, and
Table 3 Factor analysis results (Utah, January-December 2013)
Factor 1: Attitudes toward vaccines. [Cronbach’s alpha:
0.903 (95 % CI: (0.880, 0.925))]
• Vaccines are a good way to protect public health.
• I do not like the idea of vaccines.a
• Vaccines are generally safe.
• Vaccines are a way to take good care of myself now
and in the future.
• Vaccines are effective.
• Vaccines are safe. In particular, HPV vaccine is safe.
Factor 2: Regular gynecological care. [Cronbach’s alpha:
0.856 (95 % CI: (0.819, 0.892))]
• Gynecological/pelvic exams are necessary to stay healthy.
• I get a Pap test/Pap smear according to my doctor’s/health
care provider’s advice.
• It is very important to have an annual pelvic exam.
Factor 3: Comfort with sexual health (care). [Cronbach’s alpha:
0.754 (95 % CI: (0.701, 0.807))]
• I am comfortable discussing sexual health issues with a
doctor or nurse.
• I am comfortable discussing sexual health issues with others
such as family or friends.
• I don’t mind getting a gynecological/pelvic exam.
Factor 4: External locus of health control 1: (medical professionals
drive health). [Cronbach’s alpha:
0.720 (95 % CI: (0.668, 0.772))]
• Having regular contact with my physician is the best way for
me to avoid illness.
• Whenever I don’t feel well, I should consult a medically
trained professional.
• Health professionals control my health.
• Regarding my health, I can only do what my doctor tells
me to do.
Factor 5: Internal locus of health control. [Cronbach’s alpha:
0.734 (95 % CI: (0.680, 0.788))]
• I am in control of my health.
•The main thing which affects my health is what I myself do.
•If I take care of myself, I can avoid illness.
• If I take the right actions, I can stay healthy.
Factor 6: External locus of health control 2: (health matter of luck).
[Cronbach’s alpha: 0.646 (95 % CI: (0.570, 0.722))]
• Luck plays a big part in determining how soon I will recover
from an illness.
• My good health is largely a matter of good fortune.
• If it’s meant to be, I will stay healthy.
Factor 7: Comfort with shots. [Cronbach’s alpha: 0.729
(95 % CI: (0.660, 0.797))]
• I am not afraid of shots.
• Shots are very painful.a
aReverse coded (6 minus response)
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higher education were also significant predictors of
vaccine initiation and completion. Cost, being in a
monogamous relationship, and novelty of the vaccine
were the main barriers against vaccination.
These findings echo previous studies that identified
knowledge-attitude-practice gaps in the context of the HPV
vaccine [39]. The differences we found between vaccinated
women and unvaccinated women regarding risk beliefs (i.e.,
the vaccine is not personally relevant because they are in a
monogamous relationship and the vaccine is too new and
more information is needed) help explain why increasing
uptake of the HPV vaccine requires targeted risk communi-
cation strategies [39]. Additionally, our study confirms one
of the most ubiquitous finding in HPV vaccine research:
the importance of a consistent and strong recommendation
of the HPV vaccine from healthcare providers [23, 40, 41].
However, our findings run counter to an earlier study
showing no association between marital status in their mul-
tivariable analysis [23]. This difference could be due to the
particular interplay between marriage, age, and religiosity in
the state of Utah.
There are limitations to the generalizability of the current
study. The majority of participants were White/Caucasian
(>80 %), had access to healthcare, and response rates were
higher in the vaccinated vs. the unvaccinated, which may
have introduced unmeasured response bias. Furthermore,
cross-sectional study design prohibits assessment of causal
relationships.
Limitations
There are limitations to the generalizability of the current
study. One of the primary limitations was the low survey
return rate. Even after incentivizing a second wave of sur-
vey dissemination, response rates totaled well under 30 %.
Therefore, our sample size was limited. Additionally, those
who vaccinated were more likely to respond than those
who did not vaccinate, leaving the potential for voluntary
Table 4 Crude and adjusted odds ratios (95 % CIs) for predictors of vaccination initiation and completion and adjustment variables
used in regression modeling (Utah, January-December 2013)
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Fig. 3 Reasons for not initiating or completing the HPV vaccine
(Utah, January-December 2013)
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response bias. Furthermore, cross-sectional study design
prohibits assessment of causal relationships.
The majority of participants were White/Caucasian
(>80 %), had access to healthcare, and response rates
were higher in the vaccinated vs. the unvaccinated, which
may have introduced unmeasured response bias.
Conclusions
The implications of these findings may help inform policies
regarding HPV vaccination education among young
women. For example, without this information pro-
grams might focus on awareness [36, 42–44], but the
results of this study illustrate that the significance of
awareness of HPV as a predictor of vaccine uptake has
diminished over time and that programs should now
focus on other variables (for example, strong and consistent
physician recommendations). Additionally, our findings in-
dicate the need for discussions of risk assessment tailored
to the young adult population since young women are sure
of their sexual behavior in a way parents may not be of
their children’s. These interventions may use our results to
take into account a patient’s education, religious affiliation
and relationship status when having such conversations.
Future research is needed to assess the impact these
tailored interventions would have on bolstering HPV
vaccination rates in the low vaccination state of Utah.
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